CONCORD, Mass., Jan. 9, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results ...
AUSTIN, Texas, April 21, 2026 (GLOBE NEWSWIRE)-- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the U.S. Food and ...
April 11, 2012 — A single indomethacin suppository administered to patients immediately after endoscopic retrograde cholangiopancreatography (ERCP) appears to significantly reduce the risk for ...
Cristcot announced the launch of Sephure, the first disposable rectal suppository applicator. With the applicator, patients can administer a suppository in less than 5 seconds. Sephure is a disposable ...
CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical ...
Medications administered per rectum (PR) are ideal for local or systemic treatment, as the rectal mucosa has a blood and lymph supply that is capable of effective systemic absorption. The rectum is ...
Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results